Home > Journals > International Angiology > Past Issues > International Angiology 2020 October;39(5) > International Angiology 2020 October;39(5):405-10

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE  AORTIC DISEASE Freefree

International Angiology 2020 October;39(5):405-10

DOI: 10.23736/S0392-9590.20.04336-9

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Midterm outcomes of 71 consecutive abdominal aortic aneurysm patients treated with the TREO stent-graft in a single center

Nicola REINA 1, Giuseppe GALZERANO 2, Salvina DILIBERTI 1, Filippo CALÌ 1, Michele SAVAIA 1, Domenico BENEVENTO 2, Carlo SETACCI 3

1 Department of Vascular Surgery, Azienda Sanitaria Provincia di Caltanissetta, Caltanissetta, Italy; 2 Department of Vascular and Endovascular Surgery, University of Siena, Siena, Italy; 3 Unit of Vascular and Endovascular Surgery, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy



BACKGROUND: Endovascular repair of abdominal aortic aneurysm (EVAR) presents an increasing role in treatment of abdominal aortic aneurysms in patients at high and mid risk for conventional surgery. Most Vascular Surgery Units need to identify a single device as workhorse in AAA treatment. Objective of this study is to analyze midterm results of consecutive unselected patients treated with the same device in a single center series.
METHODS: A retrospective analysis of a prospective database of all consecutive patients treated between January 2016 and June 2019 with the TREO device in our center. Primary outcomes of the study were AAA related mortality rate, migration rate and type 1 endoleak at 1-year follow-up.
RESULTS: During the study period 71 consecutive patients (96% male) were treated with TREO device. Technical success was achieved in all patients. Mean follow-up was 19.6 months (range: 1-42 months). Procedure related mortality was 1.4% (N.=1), No AAA related mortality, migration or type 1b endoleak were recorded during follow-up. Two cases of late type 1a endoleak were recorded, both resolved with aortic cuffing. Median shrinkage of the residual sac was 10% and 18.5% at 6 and 18 months, respectively.
CONCLUSIONS: EVAR using TREO device seems to be safe and effective treatment for unselected patients suffering AAA. Particularly this device seems to be suitable as workhorse device in a single center with skillness between open and endovascular techniques.


KEY WORDS: Endovascular procedures; Abdominal aortic aneurysm; Stents

top of page